We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

180 hedge funds and large institutions have $1.15B invested in Ligand Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 65 increasing their positions, 63 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 23

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

11% more capital invested

Capital invested by funds: $1.04B → $1.15B (+$118M)

3% more funds holding

Funds holding: 174 → 180 (+6)

3% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 63

26% less call options, than puts

Call options by funds: $1.82M | Put options by funds: $2.45M

Holders
180
Holders Change
+6
Holders Change %
+3.45%
% of All Funds
4.8%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.16%
New
30
Increased
65
Reduced
63
Closed
23
Calls
$1.82M
Puts
$2.45M
Net Calls
-$629K
Net Calls Change
+$2.74M

Top Buyers

Rank Fund Capital Flow
1
FMA
Fiduciary Management Associates
Illinois
+$15.3M
2
KI
Kalmar Investments
Delaware
+$15.1M
3
BC
Broadfin Capital
New York
+$10.4M
4
William Blair & Company
William Blair & Company
Illinois
+$5.72M
5
Invesco
Invesco
Georgia
+$5.7M

Top Sellers

Rank Fund Capital Flow
1
GAM
Gotham Asset Management
New York
-$28.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$24.2M
3
CM
Castleark Management
Illinois
-$15.9M
4
BI
BVF Inc
California
-$13M
5
TCP
TAMRO Capital Partners
Virginia
-$7.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fisher Asset Management
51
Fisher Asset Management
Washington
$4.36M +$2.43M +74,780 +132%
ABI
52
Adamant Biomedical Investments
Switzerland
$4.33M +$4.24M +130,292 New
TCIM
53
TIAA CREF Investment Management
New York
$4.25M -$294K -9,028 -7%
BBA
54
Baker Bros. Advisors
New York
$3.91M – – –
BA
55
BlackRock Advisors
Delaware
$3.85M +$115K +3,535 +3%
TCM
56
Tekla Capital Management
Massachusetts
$3.68M – – –
BIM
57
BlackRock Investment Management
Delaware
$3.38M -$207K -6,362 -6%
IA
58
Icon Advisers
Colorado
$3.27M +$1.61M +49,533 +101%
WA
59
Whitebox Advisors
Minnesota
$3.16M +$103K +3,174 +3%
WC
60
Woodstock Corp
Massachusetts
$3.13M +$347K +10,668 +13%
SCM
61
Suffolk Capital Management
New York
$2.85M +$1.06M +32,639 +61%
California Public Employees Retirement System
62
California Public Employees Retirement System
California
$2.74M -$416K -12,788 -15%
HVC
63
Healthcare Value Capital
New Jersey
$2.66M – – –
MCM
64
Mazama Capital Management
Oregon
$2.6M +$1.8M +55,352 +243%
Two Sigma Investments
65
Two Sigma Investments
New York
$2.55M -$1.19M -36,640 -32%
ARTA
66
A.R.T. Advisors
New York
$2.37M -$1.17M -35,865 -33%
BCCM
67
Blue Clay Capital Management
Minnesota
$2.21M +$2.17M +66,685 New
New York State Common Retirement Fund
68
New York State Common Retirement Fund
New York
$2.2M -$52.1K -1,603 -2%
AllianceBernstein
69
AllianceBernstein
Tennessee
$2.12M – – –
RPAM
70
Rhenman & Partners Asset Management
Sweden
$2.08M – – –
Norges Bank
71
Norges Bank
Norway
$2.05M +$2.01M +61,784 New
California State Teachers Retirement System (CalSTRS)
72
California State Teachers Retirement System (CalSTRS)
California
$2.05M -$531K -16,328 -21%
CCA
73
Catalyst Capital Advisors
New York
$1.97M +$1.17M +35,832 +153%
Wellington Management Group
74
Wellington Management Group
Massachusetts
$1.95M -$141K -4,328 -7%
Comerica Bank
75
Comerica Bank
Texas
$1.89M +$880K +27,054 +90%
1 2
3
4 5

LGND Hedge Fund Activity: Q4 2014 in Review

180 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2014, worth a combined $1.15B — up 11% from $1.04B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new LGND positions and 23 closed out — a net gain of 7 holders — while 65 added to existing stakes and 63 trimmed.

The largest buyer was Fiduciary Management Associates, opening a new position worth an estimated $15.3M. The largest seller was Gotham Asset Management, cutting an estimated $28.6M.

  • 180 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2014, up from 174 in Q3 2014.
  • Funds reported $1.15B of Ligand Pharmaceuticals stock for Q4 2014, up 11% quarter-over-quarter.
  • 30 funds opened new Ligand Pharmaceuticals positions in Q4 2014 and 23 closed out, a net change of +7 holders.
  • The largest Ligand Pharmaceuticals buyer in Q4 2014 was Fiduciary Management Associates, an estimated $15.3M added.
  • The largest Ligand Pharmaceuticals seller in Q4 2014 was Gotham Asset Management, an estimated $28.6M sold.

Based on aggregated 13F filings for Q4 2014.